The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).
 
David R. Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Evidera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi/Aventis (Inst)
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Agios (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Ascendis Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BIND Therapeutics (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); Faeth Therapeutics (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); ImClone Systems (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Lyell Immunopharma (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Peloton Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Seagan (Inst); Shenzhen Chipscreen Biosciences (Inst); Stemline Therapeutics (Inst); Synthekine (Inst); Taiho Oncology (Inst); Tango Therapeutics (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst); Zai Lab (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Maen A. Hussein
Consulting or Advisory Role - Abbvie; Abbvie; Aptitude Health; Aptitude Health; Aptitude Health; AstraZeneca; AstraZeneca; AstraZeneca; Athenex; BMS; BMS; Coherus Biosciences; CTI BioPharma Corp; Exelixis; G1 Therapeutics; IntegraConnect; IntegraConnect; IntrinsiQ; Karyopharm Therapeutics; Mirati Therapeutics; National Community Oncology Dispensing Association (NCODA); oncocyte
 
Richard Zuniga
Employment - New York Cancer and Blood Specialists
Consulting or Advisory Role - Mirati Therapeutics
 
Daruka Mahadevan
Honoraria - Caris Life Sciences; Guardant Health
Speakers' Bureau - Caris Life Sciences; Guardant Health
Travel, Accommodations, Expenses - Caris Life Sciences; Guardant Health
 
Robert Winn
Honoraria - AstraZeneca; Bristol Myers Squibb Foundation; Genentech/Roche; Philips Healthcare; Taiho Oncology
Travel, Accommodations, Expenses - Genentech
 
Walter C. Darbonne
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Patents, Royalties, Other Intellectual Property - US patent pending: Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Bongin Yoo
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Young Kim
Employment - Genentech
Stock and Other Ownership Interests - Genentech
 
Zach Whitehead
Employment - Genentech
Stock and Other Ownership Interests - Genentech
 
Ari M. Vanderwalde
Employment - Caris Life Sciences
Consulting or Advisory Role - Bristol-Myers Squibb; Caris Life Sciences; Compugen; Concerto HealthAI; Elsevier; Inivata
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Replimune (Inst)